Kibret Yimer Mazengia's picture

Kibret Yimer Mazengia

Staff Engineer
  • E-mailKibret.Mazengia@uib.no
  • Phone+47 902 36 164
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2021). Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker. Neurology: Neuroimmunology and neuroinflammation.
  • Show author(s) (2018). Expression of the onconeural protein CDR1 in cerebellum and ovarian cancer. OncoTarget. 23975-23986.
  • Show author(s) (2015). Biomarkers related to carotid intima-media thickness and plaques in long-term survivors of ischemic stroke. Translational Stroke Research. 276-283.
  • Show author(s) (2014). Paraneoplastic Hu and CRMP5 antibodies are present in smokers without cancer or neurological disease. Respirology (Carlton South. Print). 730-734.
  • Show author(s) (2013). CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLOS ONE.
  • Show author(s) (2013). Avidity of onconeural antibodies is of clinical relevance. Cancer Immunology and Immunotherapy. 1393-1396.
  • Show author(s) (2011). Onconeural antibodies: Improved detection and clinical correlations. Journal of Neuroimmunology. 166-170.
Academic lecture
  • Show author(s) (1998). Transfer of the naturally occuring plasmid pRAS1 affects the microbiological diversity in marine sediments [poster].
  • Show author(s) (1998). Transfer of the naturally occuring plasmid pRAS1 affects the microbialdiversity in marine sediments.
Thesis at a second degree level
  • Show author(s) (1999). The spread of antibiotic resistance plasmid pRAS1 in sea water.
  • Show author(s) (2012). Hu antibodies are present in smokers with chronic obstructive pulmonary disease without cancer or neurological disease. Journal of Neuroimmunology. 21-22.
  • Show author(s) (2012). Characterization of Yo antibodies. Journal of Neuroimmunology. 131-132.
  • Show author(s) (2008). Anti-ccdc104 is a potentially new onconeural antibody. Journal of Neuroimmunology. 190-191.

More information in national current research information system (CRIStin)